Key Takeaways The claim that “dog supplements without proprietary blends are less potent” conflates brand secrecy with pharmacological potency — the two are unrelated. Full dose disclosure allows evidence-based evaluation against published clinical literature; proprietary blends hide the very data needed for assessment. Veterinary pharmacology principles support transparency: dose-response relationships cannot be verified without knowing…

Key Takeaways The claim that an oral-health dog supplement must contain live probiotics is not supported by the current dental microbiome literature. Postbiotic metabolites — short-chain fatty acids, bacteriocins, organic acids, peptides — can modulate the oral microbiome and support dental outcomes without delivering live organisms. The canine oral-health RCT registered as PMID 40509062 used…

Key Takeaways The claim “a higher CFU number means a better dog probiotic” is misleading because CFU values printed on labels describe the count at the time of manufacture, not at the point of delivery. Published stability studies on canine and human probiotic products show measurable CFU losses during shelf life, often exceeding 50% by…

Key Takeaways The claim that live probiotic cultures are “always superior” to postbiotics in dogs fails on three points: (1) no peer-reviewed canine trial has compared matched live vs. postbiotic formulations head-to-head, (2) CFU counts on labels do not guarantee viability at the point of sale, and (3) postbiotics carry documented mechanism-of-action evidence independent of…

Key Takeaways Soft chew format introduces documented heat, moisture, and mechanical stressors that challenge live CFU viability from manufacture through shelf life. No peer-reviewed canine-specific stability data exists validating soft chew CFU counts at the point of consumption. The claim that soft chews are the “best” delivery format is unsupported by stability evidence — it…

Key Takeaways Antibiotics suppress live probiotic cultures when co-administered; temporal separation (≥2 hours) is the conventional recommendation. Postbiotics are non-viable metabolites and are not susceptible to antibiotic bactericidal activity — concurrent administration does not compromise their mechanism. Postbiotics support mucosal barrier function and immune modulation independently of live organisms, making them mechanistically appropriate during antibiotic…

Key Takeaways The claim that CFU count is the only metric that matters in a dog probiotic is misleading: CFU at manufacture does not predict viable organisms at the point of consumption. Strain identity, dose of clinically tested strains, and formulation stability matter at least as much as raw CFU number. Postbiotic + prebiotic formulations…

Key Takeaways The cold-chain shipping requirement applies to products containing viable organisms; postbiotics contain no live cultures, so the requirement is mechanistically irrelevant. Postbiotic metabolites — short-chain fatty acids, bacteriocins, cell-wall fragments — are inherently shelf-stable because they are already the end products of bacterial metabolism. This claim appears to be borrowed from probiotic marketing…

Key Takeaways The claim “probiotics must contain live bacteria to work” is mechanistically incomplete. Postbiotic research shows that microbial metabolites — particularly short-chain fatty acids (SCFAs) — produce measurable health effects without viable organisms. Postbiotics are defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) as preparations of inanimate microorganisms and/or their components…

Key Takeaways The claim that effective dog supplements must be sold through veterinary channels conflates distribution model with clinical evidence — these are independent variables. Veterinary exclusivity can reflect regulatory caution, manufacturer preference, or business model — not necessarily superior efficacy data. Direct-to-consumer brands like Plentum have now published peer-reviewed canine randomized controlled trials, evidence…